iXensor Co., Ltd. (6734) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of iXensor Co., Ltd. TWD 5.68, price TWD 5.40, upside +5.2%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch iXensor Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
iXensor Co., Ltd. provides technology platform that turns smartphones into medical diagnostic devices through its smart color sensing technology for connected healthcare.
Show more
iXensor Co., Ltd. provides technology platform that turns smartphones into medical diagnostic devices through its smart color sensing technology for connected healthcare. It offers PixoTest Vision Analysis System(lipid), and PixoHealth Vision(app) for chronic disease; and Eveline Smart Fertility System and Eveline Care Telehealth Platform for women's health management. The company was founded in 2012 and is based in Taipei, Taiwan.
Stock analysis
iXensor Co., Ltd. (6734) currently trades at 5.40 TWD, while our model-based Fair Value estimate is 5.68 TWD, implying the stock looks roughly 4.9% fairly valued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 3.79 TWD (bear) to 7.04 TWD (bull), the price of 5.40 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
iXensor Co., Ltd. reported revenue of 26.9M TWD in FY2025 versus 24.8M TWD in FY2021, a compound +2.0%/yr. Reported net income was −47.0M TWD in FY2025.
Key figures
Market cap 277M TWD (≈ $8.7M) · P/S ratio 10.3 · EPS (TTM) −1.34 TWD · Net margin −175% · Return on equity −283% · Return on assets (EBIT) −61.8% · Operating margin −142% · Revenue (TTM) 26.9M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 70% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 5%, 6734 screens cheaper than that median.
Fair Value models
Bear 3.79 TWDFair Value 5.68 TWDBull 7.04 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.37/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+38.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.8%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−502.6% (2020) → −170.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score42 · Below median
Fair Value upside+5% · Above median
Profitability
Return on assets−40% · Bottom 25%
Net margin (TTM)−175% · Bottom 25%
Operating margin (TTM)−142% · Bottom 25%
Growth and dividend
Revenue growth19% · Top 25%
Balance sheet
Debt / equity0.44× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is iXensor Co., Ltd. (6734) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 5.68 TWD versus a price of 5.40 TWD, about +5% upside (fairly valued).
What is the fair value of 6734?
Our model-based fair value for iXensor Co., Ltd. is 5.68 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 5.40 TWD.
What is the quality score of 6734?
iXensor Co., Ltd. has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for iXensor Co., Ltd. (6734)?
Our model-based price target is the fair value of 5.68 TWD (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 3.79 TWD, optimistic scenario 7.04 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the iXensor Co., Ltd. stock forecast for 2026?
Our models put fair value at 5.68 TWD, about +5% upside versus a price of 5.40 TWD (fairly valued). Cautious scenario 3.79 TWD, optimistic scenario 7.04 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of iXensor Co., Ltd. (6734)?
iXensor Co., Ltd. reported trailing-twelve-month revenue of about 26.9M TWD (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of iXensor Co., Ltd. (6734)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For iXensor Co., Ltd. it is 5.68 TWD per share (as of Sep 24, 2026), against a price of 5.40 TWD. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is iXensor Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 6734 trades below its calculated fair value: price 5.40 TWD, fair value 5.68 TWD, a gap of about +5% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6734?
No. The price is what the market pays today (5.40 TWD); the fair value is what the company's own numbers justify (5.68 TWD). For iXensor Co., Ltd. the two are 0.2780 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is iXensor Co., Ltd. worth?
The market values iXensor Co., Ltd. at about 277M TWD (market capitalisation, as of Sep 24, 2026). Per share that is 5.40 TWD; our models calculate a fair value of 5.68 TWD per share.
What do the bullish and bearish scenarios say about 6734?
Our models span a range for iXensor Co., Ltd.: cautious scenario 3.79 TWD, base 5.68 TWD, optimistic 7.04 TWD per share (as of Sep 24, 2026, price 5.40 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of iXensor Co., Ltd. (6734)?
Balance-sheet figures for iXensor Co., Ltd. (as of Sep 24, 2026): return on equity −283.4%, debt of 0.44 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 6734 from its 52-week high?
iXensor Co., Ltd. trades at 5.40 TWD, about 70% below its 52-week high of 17.85 TWD and 8% above the low of 5.00 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 5.68 TWD is for.
Which stocks are comparable to iXensor Co., Ltd.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is iXensor Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 5.40 TWD, calculated fair value 5.68 TWD (+5%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6734 calculated?
We run iXensor Co., Ltd. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 5.68 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. iXensor Co., Ltd. currently trades 5 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of iXensor Co., Ltd. (6734)?
The closing price on Sep 24, 2026 was 5.40 TWD. Our model-based fair value is 5.68 TWD, about +5% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with iXensor Co., Ltd. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (3.79 TWD to 7.04 TWD) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of iXensor Co., Ltd.
How large is the market capitalisation of iXensor Co., Ltd. (6734)?
The market capitalisation of iXensor Co., Ltd. is 277M TWD (≈ $8.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of iXensor Co., Ltd. (6734)?
The price-to-sales ratio of iXensor Co., Ltd. is 10.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of iXensor Co., Ltd. (6734)?
Earnings per share at iXensor Co., Ltd. are −1.34 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of iXensor Co., Ltd. (6734)?
The net margin of iXensor Co., Ltd. is −175% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of iXensor Co., Ltd. (6734)?
The return on equity (ROE) of iXensor Co., Ltd. is −283% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of iXensor Co., Ltd. (6734)?
On an EBIT basis the return on assets of iXensor Co., Ltd. is −61.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of iXensor Co., Ltd. (6734)?
The operating margin of iXensor Co., Ltd. is −142% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at iXensor Co., Ltd. (6734)?
Revenue at iXensor Co., Ltd. is growing +19.0% versus a year earlier (3y avg −36.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does iXensor Co., Ltd. (6734) generate?
The free cash flow of iXensor Co., Ltd. is −37.3M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does iXensor Co., Ltd. (6734) carry?
The net debt of iXensor Co., Ltd. is 817K TWD (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch iXensor Co., Ltd. in the live analysis
One click puts iXensor Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
